Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. et al

  1. July 09, 2024

    HEC Can't Get Damages Over Injunction In Novartis Feud

    A Delaware federal court on Tuesday shot down HEC Pharm Co.'s bid for damages stemming from a preliminary injunction against it over the launch of a generic version of Novartis Pharmaceuticals' blockbuster multiple sclerosis treatment Gilenya.

  2. August 17, 2020

    Novartis' MS Drug Patent Upheld And Generic Ruled Infringing

    Novartis Pharmaceuticals Corp. beat back a challenge to its blockbuster multiple sclerosis drug Gilenya in a Delaware federal court ruling unsealed on Monday, with the judge finding Novartis' patent valid and holding that a planned generic by HEC Pharm infringed.

  3. March 02, 2020

    Hetero, Zydus Settle Novartis MS Drug Suits Before IP Trial

    Generic-drug makers Hetero and Zydus have each reached last-minute settlements to avoid an infringement trial set for Monday over their versions of Novartis Pharmaceuticals Corp.'s blockbuster multiple sclerosis drug Gilenya.

  4. June 17, 2019

    Mylan Escapes Novartis MS Drug Patent Suit

    Mylan Pharmaceuticals Inc. was able to evade a patent suit from Novartis seeking to block generic versions of its multiple sclerosis drug Gilenya when a judge said Monday that Delaware federal court isn't the right venue for the case.